Regenxbio Stock Price, News & Analysis

The FDA has accepted and granted Priority Review for REGENXBIO's (NASDAQ: RGNX) Biologics License Application (BLA) for RGX-121, a potential first-in-class gene therapy for Hunter syndrome (MPS II). The FDA has set a PDUFA target action date of November 9, 2025.

RGX-121 has received multiple FDA designations including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and RMAT. Under a partnership announced in January 2025, NS Pharma (Nippon Shinyaku subsidiary) will lead U.S. commercialization post-approval, while REGENXBIO maintains commercial manufacturing and supply chain responsibilities. If approved, REGENXBIO would retain rights to a potential Priority Review Voucher.

The one-time treatment aims to address both neurodevelopmental and systemic effects of Hunter syndrome, potentially replacing current weekly enzyme replacement therapy.

REGENXBIO (RGNX) reported significant progress in Q1 2025, with a net income of $6.1 million ($0.12 per share) compared to a loss of $63.3 million in Q1 2024. Revenue surged to $89.0 million, up from $15.6 million year-over-year, largely due to the Nippon Shinyaku partnership. The company's cash position strengthened to $272.7 million, expected to fund operations into H2 2026. Key pipeline developments include: RGX-202 for Duchenne muscular dystrophy advancing toward BLA submission in mid-2026, clemidsogene lanparvovec's BLA acceptance expected May 2025, and surabgene lomparvovec's pivotal data for wet AMD expected in 2026. The Nippon Shinyaku partnership brought a $110 million upfront payment with potential for $700 million in additional milestone payments.

REGENXBIO (RGNX) will present multiple studies at the American Society of Gene & Cell Therapy 28th Annual Meeting in New Orleans from May 13-17, 2025. The presentations will showcase the company's gene therapy capabilities across research, development, and manufacturing. Key highlights include:

- Late-stage clinical trial data for RGX-121 (clemidsogene lanparvovec) for MPS II treatment and RGX-202 for Duchenne muscular dystrophy

The company will deliver three oral presentations focusing on: • Commercial manufacturing process for RGX-202 • RGX-121 gene therapy for neuronopathic mucopolysaccharidosis • RGX-202 interim clinical data for Duchenne muscular dystrophy

Additionally, five poster presentations will cover various aspects of AAV vector development, testing methods, and blood-brain barrier crossing vectors.

REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025. The company will be present at five major healthcare and biotech events:

- BofA Securities Health Care Conference in Las Vegas (May 13)
- RBC Global Healthcare Conference in New York (May 20)
- H.C. Wainwright BioConnect in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
- UBS Spring Biotech Conference in New York (June 24)

Select presentations and fireside chats will be available via webcast on REGENXBIO's website, with recordings accessible for approximately 30 days after each event.

REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Monday, May 12, at 4:30 p.m. ET to present its financial performance for the first quarter ending March 31, 2025, along with recent operational updates.

The company has provided two access options for interested parties:

• General listeners can join via a webcast link
• Analysts can participate in the Q&A session through a separate dedicated link

A recording of the webcast will be made available on REGENXBIO's investor website approximately two hours after the call concludes. Participants are encouraged to connect 15 minutes before the scheduled start time.

REGENXBIO (NASDAQ: RGNX) has reported positive interim data from the AFFINITY DUCHENNE® trial of RGX-202, their investigational gene therapy for Duchenne muscular dystrophy. Key highlights include robust microdystrophin expression levels, with a 3-year-old patient showing 122.3% expression compared to control, and a 7-year-old patient showing 31.5%.

The therapy demonstrates the highest reported vector genome copies (4.9-55.4) measured by qPCR across approved or investigational gene therapies. Safety data as of February 21, 2025, shows RGX-202 was well-tolerated with no serious adverse events. Common side effects included nausea, vomiting, and fatigue, which all resolved.

The Phase III portion of the trial is currently enrolling ambulatory patients aged 1 and above, with BLA submission targeted for mid-2026. Previously reported data from November 2024 showed functional improvements in all five initial participants, exceeding external natural history controls. Additional interim functional data is expected in the first half of 2025.

REGENXBIO (RGNX) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its gene therapy pipeline. The company submitted a Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) for MPS II treatment, with potential FDA approval expected in H2 2025.

Key financial metrics include: Cash position of $244.9 million as of December 31, 2024, full-year revenues of $83.3 million, and a net loss of $227.1 million ($4.59 per share). The company secured a strategic partnership with Nippon Shinyaku worth up to $810 million, including $110 million upfront.

Pipeline updates include: RGX-202 pivotal trial for Duchenne Muscular Dystrophy is 50% enrolled with completion expected in 2025 and BLA filing planned for mid-2026. The AbbVie-partnered retinal program continues advancing with pivotal data for surabgene lomparvovec in wet AMD expected in 2026.

REGENXBIO (RGNX) has announced upcoming presentations of new interim biomarker data from their Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a treatment for Duchenne muscular dystrophy. The data will be presented at the 2025 MDA Clinical & Scientific Conference in Dallas from March 16-19, 2025.

Two presentations are scheduled: An interim clinical data presentation by Dr. Carolina Tesi Rocha from Stanford School of Medicine on March 19, and a pre-clinical research presentation on microdystrophin by Dr. Steven Foltz, Senior Scientist at REGENXBIO. Both presentations will be made available on REGENXBIO's website.

REGENXBIO (RGNX) has finalized its strategic partnership with Nippon Shinyaku for the development and commercialization of two gene therapy treatments: RGX-121 (clemidsogene lanparvovec) for Mucopolysaccharidosis II (Hunter syndrome) and RGX-111 for Mucopolysaccharidosis I (Hurler syndrome) in the United States and Asia.

The collaboration aims to advance these potential treatments for rare genetic disorders, with RGX-121 positioned to potentially become the first gene therapy for MPS II, targeting FDA approval by late 2025.